This trial is withdrawn!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Portopulmonary Hypertension
and you are
over 18
years old
Phase
1
2
This is a medium phase trial determining
the safety and dosage of the new treatment, as well as its efficacy.
Show me locations

The purpose

Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients. Treatment options include prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan. This study investigates the safety and efficacy of ambrisentan in portopulmonary hypertension.

Provided treatments

  • Drug: ambrisentan
Tris trial is registered with FDA with number: NCT01733095. The sponsor of the trial is Medical University of Graz and it is looking for 0 volunteers for the current phase.
Official trial title:
Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study